World Cancer Day: Uniting Research, Care, and Hope for People With Lymphoma In 2022, the International Agency for Research on Cancer at the World Health Organization (WHO) documented nearly 20 million new cancer cases worldwide. In the year 2050, the WHO projects that there will be over 35…
The Lymphoma Research Foundation is pleased to announce Anita Kumar, MD of Memorial Sloan Kettering Cancer Center and Sílvia Beà, PhD of August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and Hospital Clínic de Barcelona, to the Executive Committee of its international Mantle Cell Lymphoma Consortium (MCLC).
The Lymphoma Research Foundation is pleased to announce that Madhu Namburi of Hillsborough, CA, Managing Director and Co-Lead of Creation Strategy at General Catalyst, has been elected to its Board of Directors.
The Lymphoma Research Foundation is pleased to announce that John Roussel of Scottsdale, AZ, a lymphoma survivor and accomplished business executive, has joined its Board of Directors.
The U.S. Food and Drug Administration (FDA) Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma December 5, 2025 – On December 5, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (Breyanzi, Juno…
Managing Cancer Fatigue: Tips for Boosting Energy Whether it’s one of your initial symptoms or a side effect of treatment, fatigue and feelings of tiredness are very common when dealing with a lymphoma diagnosis. Usually, ordinary fatigue can be remedied…
The U.S. Food and Drug Administration (FDA) Approves Pirtobrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma December 3, 2025 – On December 3, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved pirtobrutinib (Jaypirca, Eli…
Challenge Yourself for a Cause: Running with the Lymphoma Research Foundation Running a half-marathon or a full marathon is hard enough on its own, but doing it to raise money for an organization might seem even trickier: how do you…
The U.S. Food and Drug Administration (FDA) Approves Epcoritamab-bysp for Follicular Lymphoma Indications November 18, 2025 – On November 18, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and…
The Lymphoma Research Foundation – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services – today announced the election of Kristi Hendriks of Boston, MA to its Board of Directors.
